Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2605541 versus insulin glargine in adults with type 2 diabetes previously treated with basal insulin
2011-005866-39Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2012
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3 trial of insulin peglispro and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline. Started Feb 2012; status: completed.
02
Drugs
insulin peglisproinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-005866-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005866-39.